The global demand for replacement tissues and organs significantly outstrips the supply from traditional transplantation methods, leading to extensive waiting lists and substantial healthcare costs for managing chronic diseases. This scarcity necessitates the development of advanced therapeutic alternatives that can regenerate or replace damaged biological structures.

Cells for Cells is a regenerative medicine company focused on developing advanced therapies and implants to address unmet needs in chronic diseases. The company leverages expertise in tissue engineering, biomaterials, and cell and exosome therapies to create innovative solutions. Additionally, Cells for Cells develops life science tools designed to accelerate research and development processes, with a strategy for out-licensing these technologies. This multi-faceted approach aims to reduce barriers to accessing advanced therapeutic products and improve patient outcomes.

Development of advanced implants by combining smart biomaterials with tissue engineering techniques and cellular components.

Creation of cell and exosome-based therapeutic products derived from allogeneic Mesenchymal Stem Cells (MSCs) and their extracellular vesicles.

Focus on tissue-engineered solutions for cardiovascular and orthopedic indications, including bioengineered vascular grafts and bioinks for cartilage regeneration.

Production of cell and exosome therapies in an ISO 9001-certified GMP laboratory.

Development of life science tools, such as cell culture media for exosome production, potency test devices, and in situ bioprinting devices, intended for out-licensing.

Extensive research and development pipeline supported by a significant number of patent filings, clinical trials, and scientific publications.

The primary target audience includes patients with chronic diseases requiring advanced therapies, healthcare providers seeking innovative treatment options, and pharmaceutical or biotech companies interested in licensing novel life science tools.